# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $21 pric...
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price t...
Oppenheimer analyst Matthew Biegler maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price targ...
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate o...
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price t...
HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $21 pric...
Oppenheimer analyst Matthew Biegler maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $17 price t...
Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.